Navigation Links
Researcher tests promising drug on those with Down syndrome
Date:8/2/2011

AURORA, Colo. (Aug. 1, 2011) A University of Colorado School of Medicine scientist is completing a major clinical trial on a drug that could boost cognitive function in those with Down syndrome, significantly improving their quality of life and representing a potential milestone in research on this genetic condition.

"We are hoping to enhance memory and learning in those with Down syndrome," said Alberto Costa, MD, PhD, an associate professor of medicine and the neuroscientist leading the effort. "We have been studying this drug for three years and are now ready to analyze the data on our trial. Our team at the University of Colorado and Children's Hospital Colorado expects to have the results in the next two or three months."

Costa, whose work was chronicled in last Sunday's New York Times Magazine, is testing the drug memantine, currently used to relieve symptoms of Alzheimer's disease, in 39 people with Down syndrome. About half received the drug and the others a placebo. In 2007, Costa demonstrated that memantine could improve memory function in mice with Down syndrome.

And now, for the first time, he is taking a drug effective in the treatment of learning and memory deficits in mice with Down syndrome and applying it to humans, a move described by the New York Times as "a milestone in the history of Down syndrome research."

Costa is no disinterested researcher. His 16-year-old daughter Tyche named for the Greek goddess of Fortune - has Down syndrome. Like others with the condition, she faces the specter of a steady decline in mental functioning as she gets older and a roughly 20 percent chance of getting Alzheimer's in her 50's. After that diagnosis, death is often just five years away.

"I feel I am racing the clock to find something that will at least keep her functioning at the level she is at now," Costa said. "As they age, parts of their brain will shrink and their functions will diminish."

Costa is actively pursuing links between Down and Alzheimer's disease. He says babies born with Down often carry the biological markers for Alzheimer's.

"They have the disease from the get go," he said.

Costa says the world is awash in false assumptions about Down syndrome ranging from distortions on life expectancy to educational limitations. In fact, depending on the severity of their condition, those with Down can live into their 70s, attend college, live independently and hold down jobs.

"If we are successful, it will increase hope and expectations for those with Down syndrome," Costa said. "Right now there are drugs for the signs and symptoms of medical conditions more frequent in those with Down syndrome, but nothing to improve brain function. In fact, the prevailing wisdom has been that there is essentially nothing you can do to boost memory and learning in this group. Hopefully, we can prove them wrong."

But he and other Down researchers face an overall lack of federal funding, especially when compared to other diseases and disorders.

Costa has been supported by Forest Pharmaceuticals which is funding the clinical trial, the Linda Crnic Institute for Down Syndrome, the Coleman Institute for Cognitive Disabilities and the National Institute of Child Health and Development, part of the National Institutes of Health.

"Clearly these funding sources are the unsung heroes," Costa said. "They may not get the attention or publicity but I can assure you that our efforts and the future of those with Down syndrome would be seriously compromised without their continued generosity."


'/>"/>

Contact: David Kelly
david.kelly@ucdenver.edu
303-315-6374
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. U of M researchers use improved imaging technique; discover a better approach to diagnosing epilepsy
2. RUB researchers decipher the molecular basis of blue-green algae
3. Researchers discover the mechanism that determines cell position in the intestinal epithelium
4. Caltech researchers increase the potency of HIV-battling proteins
5. Researchers tap yeasts as source of green surfactants
6. Lawson researchers take control of cancer
7. U researchers look to dogs to better understand intricacies of bone cancer
8. Penn researchers help graft olfactory receptors onto nanotubes
9. U of M researchers may have discovered key to help women fight infections during pregnancy
10. Behavior 2011 to draw global contingent of more than 1,100 animal researchers to IU next week
11. U of M researchers discover gene required to maintain male sex throughout life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... and SAN FRANCISCO , Feb. ... regenerative medicine company, and Beyond Type 1, a not-for-profit ... 1 diabetes, today announced a grant from Beyond Type ... cure for type 1 and other insulin-requiring diabetes.  ... been developing innovative stem cell-derived cell replacement therapies with ...
(Date:2/22/2017)...  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Biocom Global Life Science Partnering Conference.  The presentation will ... the Torrey Pines Lodge, in San Diego.  ... who have chosen our company, amongst numerous others, to ... and clinical researchers," said Mr. Chen. "In contrast to ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading provider of educational ... is pleased to announce the launch of a new scholarship for young scientists seeking ... This merit-based scholarship is open to all high school seniors, 17 years or older; ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... the addition of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, ... Pennside. , Perkins joins Pennside after more than a decade with leading ...
Breaking Biology Technology: